Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. May 24, 2020; 11(5): 260-274
Published online May 24, 2020. doi: 10.5306/wjco.v11.i5.260
Published online May 24, 2020. doi: 10.5306/wjco.v11.i5.260
CITED2 and the modulation of the hypoxic response in cancer
Mónica T Fernandes, School of Health, Universidade do Algarve, Campus of Gambelas, Faro 8005-139, Portugal
Mónica T Fernandes, Sofia M Calado, Leonardo Mendes-Silva, José Bragança, Centre for Biomedical Research, Universidade do Algarve, Campus of Gambelas, Faro 8005-139, Portugal
Mónica T Fernandes, Sofia M Calado, Leonardo Mendes-Silva, José Bragança, Algarve Biomedical Centre, Faro 8005-139, Portugal
Leonardo Mendes-Silva, José Bragança, Department of Biomedical Sciences and Medicine, Universidade do Algarve, Campus of Gambelas, Faro 8005-139, Portugal
Author contributions: Fernandes MT and Bragança J conceived this article and its contents; Fernandes MT, Calado SM and Mendes-Silva L wrote the first draft of the manuscript; Mendes-Silva L prepared the figures; Bragança J revised the manuscript; and all authors approved the final version.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: José Bragança, PhD, Assistant Professor, Department of Biomedical Sciences and Medicine, CBMR-Centre for BioMedical Research, Universidade do Algarve, Campus of Gambelas, Building 8, Room 2.22, Faro 8005-139, Portugal. jebraganca@ualg.pt
Received: February 27, 2020
Peer-review started: February 27, 2020
First decision: April 7, 2020
Revised: April 13, 2020
Accepted: May 12, 2020
Article in press: May 12, 2020
Published online: May 24, 2020
Peer-review started: February 27, 2020
First decision: April 7, 2020
Revised: April 13, 2020
Accepted: May 12, 2020
Article in press: May 12, 2020
Published online: May 24, 2020
Core Tip
Core tip: Hypoxia is a common feature of many cancers. In response to hypoxia, hypoxia-inducible factor 1 (HIF-1) is stabilized and activates downstream target-genes participating in crucial aspects of cancer biology, such as angiogenesis, cell survival, glucose metabolism and invasion. CITED2 is a negative regulator of HIF with demonstrated roles in various types of cancer. Therefore, CITED2 can potentially modulate HIF effects in cancer and constitute a novel target for therapies. Herein, we compile the roles reported for CITED2 in health and disease, namely through the modulation of HIF activity. We also discuss the various context-dependent roles for CITED2 in cancer.